



**UNIVERSITI PUTRA MALAYSIA**

***SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW PYRAZOLINE  
DERIVATIVES OF DIARYLPENTADIENONE***

**ADAM FARUK AUWAL**

**FS 2021 9**



**SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW PYRAZOLINE  
DERIVATIVES OF DIARYLPENTADIENONE**

By

**ADAM FARUK AUWAL**

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,  
in Fulfilment of the Requirements for the Degree of Master of Science**

**July 2020**

## **COPYRIGHT**

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

## SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW PYRAZOLINE DERIVATIVES OF DIARYLPENTADIENONE

By

ADAM FARUK AUWAL

July 2020

**Chairman : Siti Munirah binti Mohd. Faudzi, PhD**  
**Faculty : Science**

Diarylpentadienone and pyrazoline analogues were reported to have excellent pharmacological activities including antioxidant, anti-inflammation, and anti-cancer with extremely low toxicity. A number of synthetic phenolic antioxidants such as butylated hydroxytoluene (BHT) and butylated hydroxy anisole (BHA) have been widely used in the food industry, cosmetics, and the therapeutic industry, however, have been reported to be dangerous to humans due to their high volatility, instability at elevated temperature and its carcinogenic nature. Thus, led to the growing needs for new antioxidant agents for an alternative safe treatment. A series of the diarylpentadienones (**1-10**) are firstly prepared using Claisen-Schmidt condensation reaction, before further reacted with hydrazine hydrate under reflux to obtain the new series of pyrazoline analogues (**11-19**). The structures of the synthesized compounds were confirmed via  $^1\text{H}$ -,  $^{13}\text{C}$ - and 2-dimensional Nuclear Magnetic resonance (NMR) as well as Fourier Transform Spectroscopy (FTIR) and Direct injection-Mass Spectroscopy (DIMS) analyses. Following that, the antioxidant capacity of the synthesized molecules is determine using 2,2-diphenyl-1-picrylhydrazine (DPPH) radical and nitric oxide (NO) scavenging assays while quercetin is use as the positive control. The results disclose that compounds 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (**4**) and 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1*H*-pyrazol-1-yl)ethenone (**16**) show good activity in the DPPH free radical scavenging activity with  $\text{IC}_{50}$  values of  $1.32 \pm 0.015 \mu\text{g/mL}$  and  $1.55 \pm 0.029 \mu\text{g/mL}$  when compared to standard quercetin ( $\text{IC}_{50}$  :  $1.61 \pm 0.010 \mu\text{g/mL}$ ); and significant NO scavenging activity with  $\text{IC}_{50}$  values of  $6.13 \pm 0.089 \mu\text{g/mL}$  and  $5.97 \pm 0.081 \mu\text{g/mL}$  in comparison to the standard quercetin and gallic acid with  $\text{IC}_{50}$  values of  $1.91 \pm 0.006 \mu\text{g/mL}$  and  $0.88 \pm 0.010 \mu\text{g/mL}$ , respectively. Meanwhile, other compounds demonstrate moderate to lower DPPH and NO scavenging activity. Simple SAR study reveal that remarkable antioxidant properties depends on the presence of 2,4-dimethoxy phenyl ring on diarylpentadienone and 3-flouro phenyl ring on the pyrazoline derivatives. It is also proposed to prevent the use of high electron-

donating group on pyrazoline if aimed to be having a potential antioxidant. Additionally, the compounds are also tested against selected acne-causing bacteria [*Propionibacterium acnes* (*P. acne*), *Staphylococcus epidermidis* (*S. epidermidis*) and *Staphylococcus aureus* (*S. aureus*)] and *Candida albicans* (*C. albicans*), through disc diffusion assay (DDA). However, it is noticeable that all molecules are ineffective towards the antibacterial and anti-candida assays. Therefore, it is conceivably concluded that diarylpentadienone and pyrazoline derivatives are potent families as antioxidant agents.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

## SINTESIS DAN PENILAIAN BIOLOGI TERBITAN BARU PIRAZOLIN DARIPADA DIARILPENTADIENON

Oleh

ADAM FARUK AUWAL

Julai 2020

Pengerusi : Siti Munirah binti Mohd. Faudzi, PhD  
Fakulti : Sains

Analog diarilpentadienon dan pirazolin dilaporkan mempunyai aktiviti farmakologi yang sangat baik termasuk antioksidan, anti-radang dan anti-kanser dengan tahap toksik yang sangat rendah. Sejumlah antioksidan fenolik sintetik seperti hidroksitoluena terbutilasi (BHT) dan hidroksianisol terbutilasi (BHA) telah banyak digunakan dalam industri makanan, kosmetik dan terapeutik, bagaimanapun, dilaporkan berbahaya bagi manusia kerana kemeruwapan yang tinggi, ketidakstabilan pada suhu tinggi dan sifat karsinogeniknya. Hal ini mendorong kepada meningkatnya keperluan untuk mencari agen antioksidan baru sebagai rawatan alternatif yang selamat. Satu siri diarilpentadienon (**1-10**) dihasilkan menggunakan tindak balas kondensasi Claisen-Schmidt, kemudiannya bertindak balas dengan hidrazin hidrat untuk mendapatkan siri analog pirazolin baru (**11-19**). Struktur sebatian yang disintesis disahkan melalui  $^1\text{H}$ -,  $^{13}\text{C}$ - dan dua dimensi resonans magnetik nuklear (NMR) serta spektroskopi inframerah transformasi Fourier (FT-IR) dan spektrometri jisim suntikan langsung (DI-MS). Kemudian, keupayaan antioksidan molekul yang disintesis diuji menggunakan ujian radikal 2,2'-difenil-1-pikrilhidrazil (DPPH) dan nitrik oksida (NO) sementara kuersetin digunakan sebagai kawalan positif. Keputusan mendedahkan sebatian 1-(2,4-dimetoksifenil)-5-(4-metoksifenil)penta-2,4-dien-1-on (**4**) dan 1-(3-(3-fluorofenil)-5-(4-metoksistiril)-4,5-dihidro-1*H*-pirazol-1-il)ethenon (**16**) menunjukkan aktiviti yang baik dalam aktiviti perencatan radikal bebas DPPH dengan nilai  $\text{IC}_{50}$   $1.32 \pm 0.015$   $\mu\text{g/mL}$  dan  $1.55 \pm 0.029$   $\mu\text{g/mL}$  jika dibandingkan dengan standard kuersetin ( $\text{IC}_{50}$  :  $1.61 \pm 0.010$   $\mu\text{g/mL}$ ); dan aktiviti perencatan NO yang signifikan dengan nilai  $\text{IC}_{50}$   $6.13 \pm 0.089$   $\mu\text{g/mL}$  dan  $5.97 \pm 0.081$   $\mu\text{g/mL}$  berbanding dengan standard kuersetin dan asid gallik dengan nilai  $\text{IC}_{50}$   $1.91 \pm 0.006$   $\mu\text{g/mL}$  dan  $0.88 \pm 0.010$   $\mu\text{g/mL}$ , masing-masing. Sementara itu, sebatian lain menunjukkan aktiviti DPPH dan NO dari sederhana hingga rendah. Kajian SAR menunjukkan bahawa sifat antioksidan yang baik bergantung pada kehadiran cincin 2,4-dimetoksifenil pada diarilpentadienon dan cincin 3-fluorofenil pada terbitan pirazolin. Kajian ini menyarankan pencegahan penggunaan kumpulan yang melepaskan elektron tinggi

pada pirazolin untuk memiliki potensi antioksidan yang lebih baik. Selain itu, sebatian-sebatian tersebut juga diuji terhadap bakteri penyebab jerawat terpilih [*Propionibacterium acnes* (*P. acnes*), *Staphylococcus epidermidis* (*S. epidermidis*) dan *Staphylococcus aureus* (*S. aureus*)] dan kulat *Candida albicans* (*C. albicans*), melalui ujian penyebaran cakera (DDA). Walau bagaimanapun, semua sebatian tidak berkesan sebagai antibakteria dan antikulat. Oleh itu, dapat disimpulkan bahawa terbitan diarilpentadienon dan pirazolin adalah kumpulan yang kuat sebagai agen antioksidan.



## ACKNOWLEDGEMENTS

In the name of Allah, the most Beneficent and the most merciful. All praises are due to Almighty Allah S.W.T., for giving me the strength and endurance to finish this study and complete the thesis.

I would like to express my deepest gratitude to my supervisor, Dr. Siti Munirah Binti Mohd Faudzi who supported me throughout this study, and for spending her valuable time for the success of this project. I am blessed enough to have her as my supervisor. May Allah reward her abundantly, bless her children and the entire family and make the gentle souls of her late or alive parents rest in perfect peace Ameen.

I am also indebted and to all academic and non-academic staff of Department of Chemistry and Laboratory of Natural Products, Institute of Bioscience, Universiti Putra Malaysia for their guidance and full cooperation throughout the period.

I will not forget all the people who gave all their efforts in helping me to write this report, my appreciations also goes to all my colleagues especially Mohanapriya Gunasekharan, Maryam Aisyam Abdullah, Khairul Naim M.D. Padzil, Siti Zulaikha Abd Ghafar, Hamza Ahmad Pantami, Shazeli Zain, Faris Osman, Muhammad Safwan, and Yahya Yakubu for their guidance and support.



This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Siti Munirah binti Mohd Faudzi, PhD**

Senior Lecturer  
Faculty of Science  
Universiti Putra Malaysia  
(Chairman)

**Nadiah binti Mad Nasir, PhD**

Senior Lecturer  
Faculty of Science  
Universiti Putra Malaysia  
(Member)

**Lam Kok Wai, PhD**

Associate Professor  
Faculty of Pharmacy  
University Kebangsaan Malaysia  
(External Member)

---

**ZALILAH MOHD SHARIFF, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 09 September 2021

## Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name and Matric No.: Adam Faruk Auwal, GS53789

## Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: \_\_\_\_\_  
Name of Chairman  
of Supervisory  
Committee: Dr. Siti Munirah binti Mohd Faudzi

Signature: \_\_\_\_\_  
Name of Member  
of Supervisory  
Committee: Dr. Nadiah binti Mad Nasir

Signature: \_\_\_\_\_  
Name of Member  
of Supervisory  
Committee: Associate Professor Dr. Lam Kok Wai

## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	v
<b>APPROVAL</b>	vi
<b>DECLARATION</b>	viii
<b>LIST OF TABLES</b>	xiii
<b>LIST OF FIGURES</b>	xiv
<b>LIST OF SCHEMES</b>	xvi
<b>LIST OF ABBREVIATIONS</b>	xvii
<b>LIST OF SYMBOLS</b>	xix
<b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	<b>1</b>
1.1 General introduction	1
1.2 Problem Statement	6
1.3 Objectives of the study	6
<b>2 LITERATURE REVIEW</b>	<b>7</b>
2.1 Antioxidant	7
2.2 Antibacterial agents	8
2.3 Anticandidal agents	9
2.4 Diarylpentanoids	10
2.4.1 Synthesis	10
2.4.2 Pharmacological activities	10
2.5 Pyrazolines derivatives	13
2.5.1 Synthesis	14
2.5.2 Pharmacological activities	14
2.6 Structure activity relationship (SAR)	16
2.7 Conclusion	16
<b>3 MATERIALS AND METHODS</b>	<b>17</b>
3.1 Chemicals and reagents	17
3.2 Instrumentations	18
3.2.1 Melting Points	18
3.2.2 Gas Chromatography-Mass Spectrometry (GC-MS)	18
3.2.3 Nuclear Magnetic Resonance	18
3.2.4 Fourier Transform Infrared Spectroscopy (FT-IR)	18
3.3 Chromatographic Methods	19
3.3.1 Thin layer chromatography (TLC)	19
3.3.2 Gravitational column chromatography	19
3.4 Synthesis	19

3.4.1	Synthesis of diarylpentadienone analogues (1-10)	19
3.4.2	Experimental data for synthesis of diarylpentadienones	20
3.4.2.1	5-(4-methoxyphenyl)-1-phenylpenta-2,4-dien-1-one (1)	20
3.4.2.2	1-(3-methoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (2)	20
3.4.2.3	5-bis(4-methoxyphenyl)penta-2,4-dien-1-one (3)	20
3.4.2.4	1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	21
3.4.2.5	1-(2-fluorophenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (5)	21
3.4.2.6	1-(3-fluorophenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (6)	21
3.4.2.7	1-(4-fluorophenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (7)	22
3.4.2.8	5-(4-methoxyphenyl)-1-(5-methylthiophen-2-yl)penta-2,4-dien-1-one (8)	22
3.4.2.9	1-(furan-2-yl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (9)	22
3.4.2.10	1-(2-fluoro-4-methoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (10)	23
3.4.3	Synthesis of pyrazoline-diarylpentadienone analogues	23
3.4.4	Experimental data for synthesis of pyrazoline-diarylpentadienone analogues	23
3.4.4.1	Synthesis of 1-(5-(4-methoxystyryl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethenone (11)	23
3.4.4.2	Synthesis of 1-(3-(3-methoxyphenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (new compound) (12)	24
3.4.4.3	Synthesis of 1-(3-(4-methoxyphenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (13)	24
3.4.4.4	Synthesis of 1-(3-(2,4-dimethoxyphenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-	

	pyrazol-1-yl)ethenone (new compound) (14)	25
3.4.4.5	Synthesis of 1-(3-(2-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (new compound) (15)	25
3.4.4.6	Synthesis of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (new compound) (16)	25
3.4.4.7	Synthesis of 1-(3-(4-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (new compound) (17)	26
3.4.4.8	Synthesis of 1-(5-(4-methoxystyryl)-3-(5-methylthiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (new compound) (18)	26
3.4.4.9	Synthesis of 1-(3-(furan-2-yl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (new compound) (19)	27
3.5	Biological activity evaluation	27
3.5.1	Determination of antioxidants capacity	27
3.5.1.1	DPPH free radical scavenging assay	27
3.5.1.2	Nitric oxide scavenging assay	28
3.5.2	Antibacterial activity determination	28
3.5.3	Anticandidal activity evaluation	28
<b>4</b>	<b>SYNTHESIS</b>	<b>29</b>
4.1	Synthesis of diarylpentadienone analogues	29
4.1.1	Retrosynthesis	29
4.2	Synthesis of pyrazoline analogues of diarylpentadienone	42
<b>5</b>	<b>BIOLOGICAL ACTIVITY EVALUATION</b>	<b>56</b>
5.1	Antioxidant activity	56
5.1.1	DPPH scavenging activity	63
5.1.2	Nitric oxide (NO) scavenging activity	64
5.2	Antibacterial and anticandidal activity	65
<b>6</b>	<b>CONCLUSION AND RECOMMENDATION</b>	<b>70</b>
6.1	Conclusion	70
6.2	Recommendation for synthesis	71
6.3	Recommendation for biological activity evaluation	71
	<b>REFERENCES</b>	<b>72</b>
	<b>APPENDICES</b>	<b>78</b>
	<b>BIODATA OF STUDENT</b>	<b>137</b>

## LIST OF TABLES

Table		Page
1.1	Structure of diarylpentadienones and pyrazoline-diarylpentadienones	4
3.1	List of chemicals used in the synthesis process	17
3.2	List of chemicals used in the biological activity evaluation process	17
3.3	Reagents used in the synthesis process	17
3.4	List of reagents used in the biological activity evaluation process	18
4.1	$^1\text{H}$ -NMR (500MHz), $^{13}\text{C}$ -NMR (126 MHz) and HMBC data of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	34
4.2	$^1\text{H}$ -, $^{13}\text{C}$ -NMR and HMBC data of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	46
5.1	DPPH and NO radical scavenging activities of the synthesized compounds	57

## LIST OF FIGURES

Figure		Page
1.1	Diarylpentanoid analogues	1
1.2	Structures of pyrazolines	2
1.3	General structure of targeted compounds	3
2.1	General scheme illustrating the main mechanism by which antioxidants works.	7
2.2	Structures of diarylpentanoids derivatives reported as nitric oxide and $\alpha$ -glucosidase inhibitors	11
2.3	Structures of diarylpentanoids derivatives reported as antioxidant agents	12
2.4	Structures of diarylpentanoids derivatives reported as antibacterial agents	13
2.5	Structures of pyrazoline derivatives reported as anticandidal agents	15
2.6	Structures of pyrazoline derivatives reported as antioxidant agents	15
4.1	$^1\text{H-NMR}$ spectrum of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	31
4.2	$^1\text{H-NMR}$ spectrum (expansion) of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	32
4.3	DI-MS spectrum of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)	34
4.4	$^{13}\text{C-NMR}$ spectrum of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	35
4.5	$^{13}\text{C-NMR}$ (expansion) spectrum of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	36
4.6	HMBC spectrum of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	37
4.7	HMBC (expansion) spectrum of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	38
4.8	COSY spectrum of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)penta-2,4-dien-1-one (4)	39
4.9	The $^1\text{H-NMR}$ spectrum of compounds 1-10	40



4.10	<sup>1</sup> H-NMR spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	43
4.11	<sup>1</sup> H-NMR (expansion) spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	44
4.12	Main connectivity of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	45
4.13	DI-MS spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	47
4.14	<sup>13</sup> C-NMR spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	48
4.15	<sup>13</sup> C-NMR (expansion) spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	49
4.16	HMBC spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	50
4.17	HMBC (expansion) spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	51
4.18	COSY spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	52
4.19	NOESY spectrum of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16)	53
4.20	The <sup>1</sup> H-NMR spectrum of compounds 11-19	54
5.1	Antibacterial activity of compounds against the <i>S. epidermidis</i>	66
5.2	Antibacterial activity of compound	67
5.3	Antibacterial activity of compounds against the <i>P. acne</i>	68
5.4	Anticandidal activity of compounds against the <i>C. albicans</i>	69

## LIST OF SCHEMES

Scheme		Page
1.1	General reaction for the synthesis of diarylpentadienones (III) and pyrazoline-diarylpentadienones (IV)	4
2.1	Pyrazoline synthesis	14
4.1	Retrosynthesis of 1-(2,4-dimethoxyphenyl)-5-(4-methoxyphenyl)	29
4.2	Reaction mechanism of Claisen-Schmidt condensation	30
4.3	Reaction mechanism of 1-(3-(3-fluorophenyl)-5-(4-methoxystyryl)-4,5-dihydro-1H-pyrazol-1-yl)ethenone (16) formation	42

## LIST OF ABBREVIATIONS

$^{13}\text{C}$	Carbon 13
$^1\text{H}$	Proton
<i>A. niger</i>	<i>Aspergillus niger</i>
ATCC	America Type Culture Collection
BHA	Butylated hydroxy anisole
BHT	Butylated hydroxytoluene
<i>C. albicans</i>	<i>Candida albicans</i>
<i>C. glabrata</i>	<i>Candida krusei</i>
<i>C. krusei</i>	<i>Candida krusei</i>
<i>C. parapsilosis</i>	<i>Candida parapsilosis</i>
$\text{CDCl}_3$	Deuterated chloroform
$\text{CH}_3\text{COOH}$	Acetic Acid
CHX	Cycloheximide
COSY	Correlation Spectroscopy
COX	Cyclooxygenase
<i>d</i>	doublet
<i>dd</i>	doublet of doublet
DI-MS	Direct Injection-Mass Spectrometry
DMSO	Dimethyl sulfoxide
DPPH	2,2-diphenyl-1-picrylhydrazyl
EtOAc	Ethyl acetate
FT-IR	Fourier Transform Infrared Spectroscopy
GC-MS	Gas chromatography-mass spectrometry
$\text{H}_2\text{SO}_4$	Sulphuric acid
$\text{H}_3\text{PO}_4$	Phosphoric acid
HCl	Hydrochloric acid

HMBC	Heteronuclear Multiple Bond Coherence
IC	Inhibitory concentration
<i>m</i>	multiplet
MCF-7	Human breast adenocarcinoma cell lines
MgSO <sub>4</sub>	Magnesium sulphate
MHA	Mueller Hinton Agar
MS	Mass spectroscopy
NaOH	Sodium hydroxide
NO	Nitric oxide
NOESY	Nuclear Overhauser Effect Spectroscopy
<i>P. acne</i>	<i>Propionibacterium acne</i>
<i>P. aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
PBS	Phosphate buffered silane
rt	Room temperature
<i>s</i>	singlet
<i>S. aureus</i>	<i>Staphylococcus aureus</i>
<i>S. epidermidis</i>	<i>Staphylococcus epidermidis</i>
<i>S. saprophyticus</i>	<i>Staphylococcus saprophyticus</i>
SDA	Sabouraud dextrose Agar
SNP	Sodium Nitroprusside
<i>t</i>	triplet
TLC	Thin layer chromatography
TMS	Tetramethyl silane
VVC	Vulvovaginal candidiasis

## LIST OF SYMBOLS


$\mu\text{g}$	Microgram
$\text{g}$	Gram
$\text{Hz}$	Hertz
$J$	Coupling constant
$\text{kg}$	Kilogram
$M$	Molarity
$m/z$	Mass to charge ratio
$\text{MHz}$	Mega hertz
$\text{ml}$	Milliliter
$\text{ppm}$	Parts per million

## CHAPTER 1

### INTRODUCTION


#### 1.1 General introduction

Diarylpentanoids are classified as analogues of curcumin, derived from curcumin structure by the lack of ethylene unit from the heptane bridge, as depicted in Figure 1.1. Previous reports indicated this particular class of compounds have received several attentions for their bioavailability and better pharmacological activities such as anti-bacterial (Liang et al., 2008), anti-inflammatory and antioxidant properties (Lam et al., 2012; Tham et al., 2010; Lee et al., 2009) which enable them to be active in treating several chronic diseases such as cancer, diabetes, sepsis and neurodegenerative diseases. Thus, diarylpentanoid system is a potential candidate for the development of several functional drugs.



**Figure 1.1 : Diarylpentanoid analogues**

Meanwhile, pyrazolines are five membered ring heterocyclic compounds having two adjacent double nitrogen atoms within the ring, as shown in Figure 1.2. It contains only one endocyclic double bond and is basic in nature (Sethi et al., 2015). Pyrazoline exhibits significant biological activities such as anti-microbial (Naik et al., 2013), anti-bacterial (Baluja and Chandra, 2012), anti-depressant (Jayaprakash et al., 2008), anti-inflammation (Burguete et al., 2007) and anti-oxidant (Babu et al., 2007).



**Figure 1.2 : Structures of pyrazolines**

Antioxidants are molecules that in small quantities are able to prevent or greatly retard the oxidation of easily oxidizable materials, or any substance when present in low concentrations compared to those of an oxidizable substrate significantly delays or prevents oxidation of those substances (Moharram & Youssef, 2014). Antioxidants are responsible for the defense mechanism of the organism against the pathologies associated to the attack of free radicals. Thus, the intake of antioxidant is involved in the prevention of degenerative diseases caused oxidative stress such as cancer, Parkinson, Alzheimer or atherosclerosis (Droge, 2002; Lee et al., 2004; Valko et al., 2007; Pisoschi & Negulescu, 2012). These agents can be classified into three main categories by their mechanism: (1) primary antioxidants, which function essentially as free radical terminators (scavengers); (2) secondary antioxidants, which are important preventive antioxidants that function by retarding chain initiation; and (3) tertiary antioxidants, which are concerned with the repair of damaged biomolecules (Daramola & Adegoke, 2011).

Antioxidants are generally divided into two groups by source; including natural and synthetic antioxidants (Gülçin et al., 2007). There are number of synthetic phenolic antioxidants such as butylated hydroxytoluene (BHT) and butylated hydroxy anisole (BHA) which have been widely used as antioxidants in the food industry, cosmetic, and the therapeutic industry. These synthetic antioxidants, however, have been reported to be dangerous to humans due to their high volatility, instability at elevated temperature and its carcinogenic nature. Thus, led to growing needs for new antioxidant agents as an alternative safe treatment (Sindhi et al., 2013).


Antibacterial agents are clinically useful compounds in the treatment of bacterial infections which may be derived from natural sources, synthetic or semi-synthetically produced. The activity of bacterial agents can be either bacteriostatic which will only stall the growth of bacterial or bactericidal, which significantly reduces the number of viable bacteria in the culture (Pankey & Sabath, 2004). Bacterial infections are one of the main causes of infectious diseases, Hence, over 50 years of extensive research have been launched to achieving new antimicrobial medicines isolated from different sources. Despite progress in development of antibacterial agents, there are still needs to find new bacterial agents due to development of multidrug resistant bacterial (Wise et al., 1998).

Meanwhile, anticandidal or antifungal are agents that kills fungi or inhibits their growth. Antifungal that kill fungi are called fungicidal while those that merely inhibit their growth are called fungistatic (Kumar & Jha, 2017). Candidiasis is a fungal

infection due to any species from the yeast *Candida* spp, a genus accounting for more than 85% of known fungemia (Ha et al., 2011). Candidiasis ranges from superficial infection, where *Candida* species can infect the mouth, skin, vagina, stomach and urinary tract (Greenspan & Greenspan, 1996). There are twenty *Candida* species that can cause disease in humans. Of these species, *C. albicans* has been the most implicated in candidiasis. It is the most common fungal pathogen in humans, can cause broad spectrum of diseases including skin, mucosal, and systemic infection (Moran et al., 2012). Antifungal/anticandidal are used to treat fungal infections in people who are at risk, including AIDS patients, cancer patients and individual taking immunosuppressants. In view of scarcity of antibacterial agents acting on cytoplasmic membrane, it is surprising to find some of the most successful groups of anticandidal/antifungal agents, including the polyenes, azole and allylamines (Kumar & Jha, 2017).


The search for new anticandidal/antifungal strategies to overcome *Candida* infections is essential and a matter of public health, due to the high mortality associated to candidiasis (Moraes & Ferreira-Pereira, 2019). The antifungal agent amphotericin B remains the gold standard treatment for candidiasis, but its toxicity underscores the need for alternative safe antifungal. There are also the azoles, a class of chemical compounds used for the treatment of candidiasis. However, *Candida* species are developing resistance to these drugs (Rothstein et al., 2001; Forrest et al., 2008). Candidiasis is costly to the patient; it not only increases patient's mortality rate but also extend patients length of stay in care centers and thus increases the total cost of medical care. Estimates show that each episode of invasive candidiasis costs approximately US\$40,000 (Ha et al., 2011).

Therefore, we aimed to study the impact of rigidity of the diarylpentadienone scaffold by incorporating the pyrazoline ring into the system on their biological activities, specifically on antioxidants, antibacterial and anticandidal. Besides, the structure-activity relationship (SAR) of the selected functional groups on both ring A and B on the selected bioactivities will be analyze too. We hypothesized the diarylpentadienones and its respective pyrazolines analogues might be a potential candidate based on the reported strong antioxidant activity (Babu et al., 2007). Consequently, the general structures and reaction scheme of the targeted compound incorporating diarylpentadienone and pyrazoline are shown in Figure 1.3 and Scheme 1.1, respectively. Meanwhile the structure of all nineteen compounds including seven new compounds are tabulated in Table 1.1.



**Figure 1.3 : General structure of targeted compounds**


















**Scheme 1.1 : General reaction for the synthesis of diarylpentadienones (III) and pyrazoline-diarylpentadienones (IV)**

**Table 1.1 : Structure of diarylpentadienones and pyrazoline-diarylpentadienones**

	Diarylpentadienone		Pyrazoline-Diarylpentadienone
1		11	
2		12*	
3		13	

Table 1.1 : Continued

4		14*	
5		15*	
6		16*	
7		17*	
8		18*	
9		19*	
10			

\*Indicates new compound

## 1.2 Problem Statement

Antioxidants are used routinely as a protection against oxidation. Several synthetic phenolic antioxidants such as butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA) have been widely used in the food industry, cosmetics, and the therapeutic industry. However, these synthetic antioxidants have been reported to be hazardous to humans, due to their high volatility, instability at elevated temperature, and its carcinogenic nature which then have led to the growing needs for new antioxidant agents as an alternative safe treatment (Sindhi et al., 2013).

Diarylpentadienones and pyrazolines analogues might be the potent candidate based on their reported strong antioxidant property (Babu et al., 2007). Hence, in this study we have designed and synthesized a series of pyrazoline analogues of diarylpentadienones. We hypothesize with a different selected functional group on both rings and increase rigidity on the diarylpentadienone scaffold, the selected bioactivities might be enhanced.

To the best of our knowledge, limited number of studies incorporated the  $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\sigma$ -unsaturated ketone moiety in a diarylpentadienone scaffold and pyrazoline analogue of diarylpentadienone in the evaluation of antioxidant, antibacterial and anticandidal properties. Therefore, we are focusing on design strategies of diarylpentadienone and pyrazoline analogue of diarylpentadienone to produce the desired antioxidant, antibacterial and anticandidal properties by studying the effect of various functional group at different positions of diarylpentadienone and pyrazoline analogue of diarylpentadienone on the selected bioactivities. The antioxidant, antibacterial and anticandidal activities were conducted at the Laboratory of Natural Products, Institute of Bioscience, UPM.

## 1.3 Objectives of the study

1. To synthesize the diarylpentadienones and its pyrazoline analogues
2. To structurally characterize the synthesized compounds via spectroscopic methods such as  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR, Nuclear Overhauser Effect Spectroscopy (NOESY), Heteronuclear Multiple bond Coherence (HBMC), Correlation Spectroscopy (COSY), Gas Chromatography-Mass Spectroscopy (GC-MS) as well as Fourier Transform Infrared Spectroscopy (FT-IR).
3. To evaluate their antioxidant activity using 2,2-diphenyl-1-picrylhydrazine (DPPH) radical and nitric oxide (NO) scavenging assays as well as their antibacterial and anticandidal efficacies using disk diffusion assay.

## REFERENCES

- Aarons, L. (2005). Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. *British Journal of Clinical Pharmacology*, 60(6), 581–583.
- Abd Ghafar, S. Z., Mediani, A., Maulidiani, Ramli, N. S., & Abas, F. (2018). Antioxidant,  $\alpha$ -glucosidase, and nitric oxide inhibitory activities of *Phyllanthus acidus* and LC–MS/MS profile of the active extract. *Food Bioscience*, 25, 134–140.
- Adams, B. K., Ferstl, E. M., Davis, M. C., Herold, M., & Kurtkaya, S. (2004). Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. *Bioorganic and Medicinal Chemistry*, 12, 3871–3883.
- Babu, V. H., Sridevi, C. H., Joseph, A., & Srinivasan, K. K. (2007). Synthesis and biological evaluation of some new pyrazolines. *Indian Journal of Pharmaceutical Sciences*, 64(3), 470–473.
- Balogh, G. T., Tarcsay, Á., & Keseru, G. M. (2012). Comparative evaluation of pK a prediction tools on a drug discovery dataset. *Journal of Pharmaceutical and Biomedical Analysis*, 67–68, 63–70.
- Bendary, E., Francis, R. R., Ali, H. M. G., Sarwat, M. I., & El Hady, S. (2013). Antioxidant and structure–activity relationships (SARs) of some phenolic and anilines compounds. *Annals of Agricultural Sciences*, 58(2), 173–181.
- Burguete, A., Pontiki, E., Hadjipavlou-Litina, D. R., Vicente, E., Solano, B., Ancizu, S., Perez-Silanes, S., Aldanaa, I., & Monge, A. (2007). Synthesis and anti-inflammatory/antioxidant activities of some new ring 3-phenyl-1(1, 4-di-N-oxide quinoxaline-2-yl)-2-propen-1-one derivatives and of their 4, 5-dihydro-(1H)-pyrazole analogues. *Bioorganic and Medicinal Chemistry Letters*, 17, 6439–6443.
- Calhella, R. C., Peixoto, D., Vilas Boas, M., Queiroz, M. R. P., & Ferreira, I. C. F. R. (2014). Antioxidant activity of aminodiarylamines in the thieno[3,2-b]pyridine series: Radical scavenging activity, lipid peroxidation inhibition and redox profile. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 29(3), 311–316.
- Carlson, H. A., & McCammon, J. A. (2000). Accommodating protein flexibility in computational drug design. *Molecular Pharmacology*, 57(2), 213–218.
- Christodoulou, M. S., Liekens, S., Kasiotis, K. M., & Haroutounian, S. A. (2010). Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity. *Bioorganic and Medicinal Chemistry*, 18(12), 4338–4350.
- Climent, M. J., Corma, A., Iborra, S., & Vely, A. (2004). Activated hydrotalcites as catalysts for the synthesis of chalcones of pharmaceutical interest. *Journal of Catalysis*, 221(2), 474–482.

- CLSI. (2002). Reference methods for dilution antifungal susceptibility testing of yeast. Approved Standard M27-A2. *National committee for clinical laboratory standard, Wayne, PA.*
- CLSI. (2012). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 9 th ed. CLSI document M07-A9. In *Clinical Laboratory Standards Institute.*
- Cosmas, S., Ekpo, D. E., Asomadu, R. O., Assor, J. O., Nnamani, V. I., & Durojaye, O. A. (2018). Review on structure-activity relationship (SAR) using antimalarial drug design as a case study. *International Journal of Scientific & Engineering Research*, 9(6), 1743–1752.
- Coutinho, E. K., Khunt, R. M., Khedkar, V. S., Chawda, R. R., Chauhan, N. A., & Parikh, A. (2012). Synthesis, antitubercular evaluation and 3D QSAR study of N-phenyl-3-(4- fluorophenyl)-4-substituted pyrazole derivatives. *Bioorganic and Medicinal Chemistry Letters*, 22(6), 666–678.
- Daramola, B., & Adegoke, G. O. (2011). Nuts and seeds in health and disease prevention (V. R. Preedy, R. R. Watson, & B. P. Vinood, Eds.).
- de Oliveira Silva, E., & Batista, R. (2017). Ferulic acid and naturally occurring compounds bearing a feruloyl moiety: a review on their structures, occurrence, and potential health benefits. *Comprehensive Reviews in Food Science and Food Safety*, 16(4), 580–616.
- Di Meo, S., Reed, T. T., Venditti, P., & Victor, V. M. (2016). Role of ROS and RNS sources in physiological and pathological conditions. *Oxidative Medicine and Cellular Longevity*, 2016, 44.
- Droge, W. (2002). Free radicals in the physiological control of cell function. *Physiological Reviews*, 82(1), 47–95.
- Du, Z. Y., Liu, R. R., Shao, W. Y., Mao, X. P., Ma, L., Gu, L. Q., & Chan, A. S. (2006). Alpha-glucosidase inhibition of natural curcuminoids and curcumin analogs. *European Journal of Medicinal Chemistry*, 41(2), 213–218.
- Forrest, G. N., Weekes, E., & Johnson, J. K. (2008). Increasing incidence of candida parapsilosis candidemia with caspofungin usage. *Journal of Infection*, 56(2), 126–129.
- Greenspan, D., & Greenspan, J. S. (1996). HIV series HIV-related oral disease. *The Lancet*, 348, 729–733.
- Gülçin, I., Elias, R., Gepdiremen, A., Boyer, L., & Köksal, E. (2007). A comparative study on the antioxidant activity of fringe tree (*Chionanthus virginicus* L.) extracts. *African Journal of Biotechnology*, 6(4), 410–418.
- Ha, J. F., Italiano, C. M., Heath, C. H., Shih, S., Rea, S., & Wood, F. M. (2011). Candidemia and invasive candidiasis: a review of the literature for the burns surgeon. *Burns*, 37(2), 181–195.

- Hurrell, R. F. (2003). Influence of vegetable protein sources on trace element and mineral bioavailability. *The Journal of Nutrition*, 133(9), 2973S-2977S.
- Jayaprakash, V., Sinha, B. N., Ucar, G., & Ercan, A. (2008). Pyrazoline-based mycobactin analogues as MAO-inhibitors. *Bioorganic and Medicinal Chemistry Letters*, 18(24), 6362–6368.
- Kiran, K., Ashok, D., Rao, B. A., Sarasija, M., & Rao, A. S. (2017). Synthesis of novel pyrazoline-based bis(1,2,3-triazole) scaffolds via click chemistry. *Journal of the Serbian Chemical Society*, 82(3), 241–251.
- Kitawat, B. S., & Singh, M. (2014). Synthesis, characterization, antibacterial, antioxidant, DNA binding and SAR study of a novel pyrazine moiety bearing 2-pyrazoline derivatives. *New J. Chem*, 38, 4290–4299.
- Kumar, A., & Jha, A. (2017). Antifungals used against Candidiasis. In *Anticandidal Agents*.
- Kumar, A., Varadaraj, B. G., & Singla, R. K. (2013). Synthesis and evaluation of antioxidant activity of novel 3,5-disubstituted-2-pyrazolines. *Bulletin of Faculty of Pharmacy, Cairo University*, 51(2), 167–173.
- Lam, K. W., Tham, C. L., Liew, C. Y., Syahida, A., Rahman, M. B. A., Israf, D. A., & Lajis, N. H. (2012). Synthesis and evaluation of DPPH and anti-inflammatory activities of 2,6-bisbenzylidenecyclohexanone and pyrazoline derivatives. *Medicinal Chemistry Research*, 21(3), 333–344.
- Lee, J., Koo, N., & Min, D. B. (2004). Reactive oxygen species, aging, and antioxidative nutraceuticals. *Comprehensive Reviews in Food Science and Food Safety*, 3(1), 21–33.
- Lee, K. H., Haryani, F., Aziz, A., Syahida, A., Abas, F., Shaari, K., & Lajis, N. H. (2009). Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for anti-inflammatory, antioxidant and anti-tyrosinase activities. *European Journal of Medicinal Chemistry*, 44(8), 3195–3200.
- Leong, S. W. (2014). Design, synthesis, anti-inflammatory activity evaluation and structure-activity relationship (SAR) study diarylpentanoid derivatives (Vol. 8).
- Leong, S. W., Awini, T., Mohd, S. M. F., Shaari, K., & Abas, F. (2019). Synthesis and biological evaluation of asymmetrical diarylpentanoids as anti-inflammatory, anti- $\alpha$ -glucosidase, and antioxidant agents. *Medicinal Chemistry Research*, 4–11.
- LÉvai, A., Patonay, T., Silva, A. M. S., Pinto, D. C. G. A., & Cavaleiro, J. A. S. (2002). Synthesis of 3-aryl-5-styryl-2-pyrazolines by the reaction of (E,E)-cinnamylideneacetophenones with hydrazines and their oxidation into pyrazoles. *Journal of Heterocyclic Chemistry*, 39(4), 751–758.
- Liang, G., Yang, S., Jiang, L., Zhao, Y., Shao, L., Xiao, J., & Li, X. (2008). Synthesis and anti-bacterial properties of mono-carbonyl analogues of curcumin.



- Lin, L., & Lee, K. H. (2006). Structure-activity relationships of curcumin and its analogs with different biological activities. *Studies in Natural Products Chemistry*, 33, 785–812.
- Lobo, V., Patil, A., Phatak, A., & Chandra, N. (2010). Free radicals, antioxidants and functional foods: impact on human health. *Pharmacognosy Reviews*, 4(8), 118–126.
- Maher, P., Akaishi, T., Schurbert, D., & Abe, K. (2010). A pyrazoline derivative of curcumin enhances memory. *Neurobiology of Aging*, 31, 706–709.
- Malki, F., Touati, A., Moulay, S., & Baltas, M. (2016). Evaluation of antioxidant activity of some mesoionic pyrimidinium betaines by three different methods. *International Journal of Chemical Engineering and Applications*, 7(6), 373–377.
- Marella, A., Rahmat, A. M., Saha, R., Tanwar, O., Akhter, M., & Mumtaz, A. M. (2013). Pyrazolines: a biological review. *Mini-Reviews in Medicinal Chemistry*, 13(6), 921–931.
- Moharram, H. A., & Youssef, M. M. (2014). Methods for determining the antioxidant activity: a review. *Alexandria Journal of Food Science and Technology*, 11(1), 31–41.
- Mohd Faudzi, S. M., Leong, S. W., Abas, F., Mohd Aluwi, M. F. F., Rullah, K., Lam, K. W., & Lajis, N. H. (2015). Synthesis, biological evaluation and QSAR studies of diarylpentanoid analogues as potential nitric oxide inhibitors. *MedChemComm*, 6(6), 1069–1080.
- Moraes, D. C., & Ferreira-Pereira, A. (2019). Insights on the anticandidal activity of non-antifungal drugs. *Journal de Mycologie Medicale*, 29(3), 253–259.
- Moran, G., Coleman, D., & Sullivan, D. (2012). An introduction to the medically important *Candida* species and candidiasis. (Edition 2; R. A. Chalderon & C. J. Clancy, Eds.). *ASM Press*.
- Motyl, M., Dorso, K., Barrett, J., & Giacobbe, R. (2005). Basic microbiological techniques used in antibacterial drug discovery. *Current Protocols in Pharmacology*, 31(1), 1–22.
- Naik, K., Prasad, A. R. G., Spoorthy, Y. N., & Ravindranath, L. R. K. R. (2013). Design, synthesis, characterization and antimicrobial evaluation of new pyrazoline-5-Ones. *Journal of Applied Pharmacy*, 4(01), 720–730.
- Naik, N., Kumar, H. V., & Swetha, S. (2011). 1,5-diphenylpenta-1,4 dien-3-ones: a novel class of free radical scavengers. *Bulgarian Chemical Communications*, 43(3), 460–464.
- Özdemir, A., Altıntop, M. D., Kaplancıklı, Z. A., Turan-Zitouni, G., Karaca, H., & Tunalı, Y. (2013). Synthesis and biological evaluation of pyrazoline derivatives bearing an indole moiety as new antimicrobial agents. *Arch.*

*Pharm. Chem. Life Sci.*, 346, 463–469.

- Özdemir, A., Sever, B., & Altıntop, M. D. (2018). New benzodioxole-based pyrazoline derivatives: synthesis and anticandidal, in silico ADMET, molecular docking studies. *Letters in Drug Design & Discovery*, 16(1), 82–92.
- Pankey, G. A., & Sabath, L. D. (2004). Clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections. *Clinical Infectious Diseases*, 38, 864–870.
- Parul, R., Kundu, S. K., & Saha, P. (2012). In vitro nitric oxide scavenging activity of methanol extracts of three bangladeshi medicinal plants. *The Pharma Innovation-Journal*, 1(12), 83–88.
- Pirmoradian, M., & Hooshmand, T. (2019). Remineralization and antibacterial capabilities of resin-based dental nanocomposites. *Applications of Nanocomposite Materials in Dentistry, 2016*, 237–269.
- Pisoschi, A. M., & Negulescu, G. P. (2012). Methods for total antioxidant activity determination: a review. *Biochemistry & Analytical Biochemistry*, 1(1), 1–10.
- Prakash, C. R., Panneerselvam, T., & Raja, S. (2010). Synthesis and evaluation of antioxidant activities of some indole-2,3-dione derivatives and analogs. *Toxicological and Environmental Chemistry*, 92(8), 1397–1407.
- Ratnam, D. V., Ankola, D. D., Bhardwaj, V., Sahana, D. K., & Kumar, M. N. V. R. (2006). Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. *Journal of Controlled Release*, 113(3), 189–207.
- Rothstein, D. M., Spacciapoli, P., Tran, L. T., Xu, T., Roberts, F. D., Dalla Serra, M., & Friden, P. (2001). Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. *Antimicrobial Agents and Chemotherapy*, 45(5), 1367–1373.
- Samshuddin, S., Narayana, B., Sarojini, B. K., Khan, M. T. H., Yathirajan, H. S., Raj, C. G. D., & Raghavendra, R. (2012). Antimicrobial, analgesic, DPPH scavenging activities and molecular docking study of some 1,3,5-triaryl-2-pyrazolines. *Medicinal Chemistry Research*, 21(8), 2012–2022.
- Sethi, R., Ahuja, M., & Jatolia, S. N. (2015). Pharmacological activities of pyrazoline derivatives. *International Journal of Pharmaceutical Sciences Review and Research*, 34(1), 228–233.
- Shankar, M., Srividya, B. K., Hemachandar, K., Sivanna, P., & Babu, M. N. (2014). Importance of structural activity relationship in computer aided drug design: a review. *European Journal of Pharmaceutical Science and Research*, 1(1), 13–16.
- Silva, V. L. M., Elguero, J., & Silva, A. M. S. (2018). Current progress on antioxidants incorporating the pyrazole core. *European Journal of Medicinal Chemistry*, 156, 394–429.



- Sindhi, V., Gupta, V., Sharma, K., Bhatnagar, S., Kumari, R., & Dhaka, N. (2013). Potential applications of antioxidants: a review. *Journal of Pharmacy Research*, 7(9), 828–835.
- Sobel, J. D. (1998). Vulvovaginal due to candida glabrata, an emerging problem. *Mycoses*, 41(2), 18–22.
- Tham, C. L., Liew, C. Y., Lam, K. W., Mohamad, A. S., Kim, M. K., Cheah, Y. K., & Israf, D. A. (2010). A synthetic curcuminoid derivative inhibits nitric oxide and proinflammatory cytokine synthesis. *European Journal of Pharmacology*, 628(1–3), 247–254.
- Tønnesen, H. H., Smistad, G., Ågren, T., & Karlsen, J. (1993). Studies on curcumin and curcuminoids. XXIII: effects of curcumin on liposomal lipid peroxidation. *International Journal of Pharmaceutics*, 90(3), 221–228.
- Valko, M., Leibfritz, D., Jan, M., Milan, M., & Joshua, T. (2007). Free radicals and antioxidants in normal physiological functions and human disease. *International Journal of Biochemistry and Cell Biology*, 39(1), 44–84.
- Wan, C., Yuan, T., Cirello, A. L., & Seeram, N. P. (2012). Antioxidant and  $\alpha$ -glucosidase inhibitory phenolics isolated from highbush blueberry flowers. *Food Chemistry*, 135(3), 1929–1937.
- Wise, R., Hart, T., & Cars, O. (1998). Antimicrobial resistance, is a major threat to public health. *British Medical Journal*, 317(7159), 609–610.
- Yanagimoto, K., Lee, K. G., Ochi, H., & Shibamoto, T. (2002). Antioxidative activity of heterocyclic compounds found in coffee volatiles produced by maillard reaction. *Journal of Agricultural and Food Chemistry*, 50(19), 5480–5484.
- Youssef, K. M., El-Sherbeny, M. A., El-Shafie, F. S., Farag, H. A., Al-Deeb, O. A., & Awadalla, S. A. A. (2004). Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents. *Archiv Der Pharmazie*, 337(1), 42–54.